Cliquez ici pour connaître notre offre FCPI

The fast pace of innovation in IT offers compelling investment opportunities

Truffle Capital is a pioneer investor in the exciting field of Energy

Biotechnology has radically transformed medicine over the past 25 years


  • “ Truffle Capital has been an industrial, strategic and financial partner to Vexim since the creation of the company in 2006 and has enabled Vexim to acquire an international role within the treatment of spine fractures. The partners of Truffle Capital are passionate entrepreneurs, keen on innovation and understand a company’s needs and its people. They have taken measured risks, helped Vexim in fulfilling its aims and accompanied us in our progress, for which we are very grateful.  ”Vexim
    Vincent Gardes / CEO

Truffle Capital is an independent European venture capital firm

Truffle Capital is an independent venture capital firm investing in Europe. Established in 2001 and with close to €700 million under management and advisory as of the 30th June 2014, Truffle Capital is an important and independent European private equity firm, specialized in investments in spin-offs from companies active in the Energy, Information Technology and Life Sciences sectors. The firm is led by a team of three General Partners with decades of successful investment and entrepreneurial experience in both Europe and in the USA.

Backed by an investment team of international experts and an experienced support team, a total of 16 professionals, Truffle Capital aims to achieve superior financial returns by leveraging its industry knowledge, extensive network, and operational experience to identify business opportunities that match latent market needs.


01-2015

THERACLION

29th January 2015 – Theraclion Reports 2014 Revenues of 800 K€

Pdf


+ read more
01-2015

NETBOOSTER

NETBOOSTER remporte deux nouveaux budgets à l’international – Capital.fr

Pdf


+ read more
01-2015

NETBOOSTER

Le 27 janvier 2015 – NetBooster remporte deux nouveaux clients internationaux : le Groupe Estée Lauder et la banque Standard Chartered

Pdf


+ read more
01-2015

IMMUNE TARGETING SYSTEMS

27th January 2015 – Valneva Grants Exclusive Worldwide License to Immune Targeting Systems for the Development of Hepatitis B Vaccines in Combination with the IC31® Adjuvant

Pdf


+ read more